Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 297
- 主要终点
- Progression-Free Survival (PFS)
研究概览
简要总结
The purpose of this study is to assess the safety and efficacy of oral abiraterone acetate plus oral prednisone and oral abiraterone acetate plus oral prednisone plus oral exemestane, each compared with oral exemestane alone, in postmenopausal women with estrogen receptor-positive (ER+) metastatic (spreading) breast cancer that has relapsed after treatment with letrozole or anastrozole.
详细描述
This is a randomized (study drug assigned by chance), open-label (all participants will know the identity of the assigned study drug) study divided into three phases, screening, treatment, and follow-up. During screening, potential patients will be assessed for study eligibility after providing signed informed consent. The treatment phase will comprise a series of 28-day cycles with continuous study treatment until breast cancer progression, when an end-of-treatment visit will be completed before the follow-up phase begins. The duration of participation in the study for an individual patient may be up to approximately 7 years, including follow-up evaluations. Patients will be evaluated for the safety and effectiveness of study treatments. During the treatment phase, patients will take the following study drugs by mouth once daily: abiraterone acetate, 1 g/day, as four 250-mg tablets, on an empty stomach, and patients must not eat for at least 1 hour after abiraterone acetate; prednisone (prednisolone when prednisone is not available), 5 mg/day; and exemestane, 25 mg/day, as a single tablet. The treatment phase will consist of a series of 28-day cycles with continuous study treatment until breast cancer progression. At the planned interim analysis, the Data Review Committee has recommended that further randomization to the abiraterone acetate alone group be stopped and that the study is to be continued otherwise.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female patients must be postmenopausal
- •ER+, Human epidermal growth factor receptor 2 (Her2) negative metastatic breast cancer
- •Disease must have been sensitive to anastrozole or letrozole therapy prior to disease progression
- •No more than two prior lines of therapy in the metastatic setting, of which no more than one was chemotherapy
- •Eastern Cooperative Oncology Group (ECOG) performance status score of <=1
- •Patients with disease confined only to bone may be included, but patients with purely sclerotic lesions may not participate in the study
排除标准
- •Prior treatment with exemestane, ketoconazole, aminoglutethimide, or a CYP17 inhibitor. Prior treatment with ketoconazole for <= 7 days is permitted and topical formulations of ketoconazole are permitted
- •Potential patients must not have taken anastrozole, letrozole, fulvestrant, or any chemotherapy for at least 2 weeks (bevacizumab for at least 3 weeks) before randomization
- •Anticancer immunotherapy or investigational agent within 4 weeks before randomization, or anticancer radiotherapy (except palliative) or anticancer endocrine therapy within 2 weeks before randomization
- •Serious or uncontrolled nonmalignant disease, including active or uncontrolled infection
- •Clinical or biochemical evidence of hyperaldosteronism or hypopituitarism
- •Any condition that, in the opinion of the investigator, would compromise the well-being of the patient or that could prevent, limit, or confound the protocol-specified assessments
研究组 & 干预措施
Abiraterone acetate + Prednisone or Prednisolone
Abiraterone acetate + Prednisone or Prednisolone Abiraterone acetate type=equal unit=mg number=250 form=tablet route=oral use 4 tablets Prednisone or Prednisolone type=equal unit=mg number=5 form=tablet route=oral use. All drugs are taken once daily.
干预措施: Abiraterone acetate + Prednisone or Prednisolone (Drug)
Abiraterone acetate + Prednisone/Prednisolone + Exemestane
Abiraterone acetate + Prednisone/Prednisolone + Exemestane Abiraterone acetate type=equal unit=mg number=250 form=tablet route=oral use 4 tablets Prednisone or Prednisolone type=equal unit=mg number=5 form=tablet route=oral use Exemestane type=equal unit=mg number=25 form=tablet route=oral use. All drugs are taken once daily.
干预措施: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane (Drug)
Exemestane
Exemestane Exemestane type=equal unit=mg number=25 form=tablet route=oral use. All drugs are taken once daily.
干预措施: Exemestane (Drug)
结局指标
主要结局
Progression-Free Survival (PFS)
时间窗: Approximately 2 years
Progression-free survival was defined as the time from randomization to first occurrence of disease progression (either radiographic or clinical), or death from any cause. PFS was determined using radiographic progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) on measurable lesions captured by computed tomography (CT) or magnetic resonance imaging (MRI). Clinical disease progression was considered only when disease progression could not be confirmed by CT or MRI, such as when the disease site is skin, bone marrow, or central nervous system.
Overall Survival (OS)
时间窗: Approximately 3 years
OS was calculated as the time from randomization to death from any cause.
次要结局
- Overall Response Rate (ORR)(Approximately 2 years)
- Clinical Benefit Rate(Approximately 2 years)
- Change From Baseline in Serum Endocrine Biomarkers (Progesterone and Testosterone) at End of Treatment(Baseline and End of treatment (approximately 2 years))
- Duration of Response(Approximately 2 years)
- Change From Baseline in Serum Endocrine Biomarkers (Estradiol and Estrone) at End of Treatment(Baseline and End of treatment (approximately 2 years))